Oxycodone
FDA-approved product (capsule, extended release, oral), marketed as Xtampza Er, Oxaydo, Oxycodone Hydrochloride and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic pain
- Drug dependence
- Pain
- Substance abuse
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural opium alkaloids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oxycodone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more66.8% AI-predicted activityagainst M. tuberculosis18 registered studies
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery
NCT00679614 · start 2007-12-17
Registered record
- Registry ID
- NCT00679614
- Conditions
- Hip Arthroplasty; Knee Arthroplasty; Spinal Anesthesia
- Interventions
- tramacet, naloxone; tramacet; Acetaminophen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-12-17
- Completion
- 2011-05-31
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHip Arthroplasty; Knee Arthroplasty; Spinal AnesthesiaInterventiontramacet, naloxone; tramacet; AcetaminophenPhasePhase 3Registry statusCompletedThe Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache
NCT00574015 · start 2007-12
Registered record
- Registry ID
- NCT00574015
- Conditions
- Toothache
- Interventions
- hydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2013-01
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionToothacheInterventionhydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)PhasePhase 4Registry statusCompletedSafety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
NCT00654069 · start 2007-09
Registered record
- Registry ID
- NCT00654069
- Conditions
- Pain
- Interventions
- Placebo; Acurox 5/30 mg; Acurox 7.5/30
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2008-03
- Enrolment
- 405
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionPlacebo; Acurox 5/30 mg; Acurox 7.5/30PhasePhase 3Registry statusCompletedA Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100086 · start 2007-01
Registered record
- Registry ID
- NCT01100086
- Conditions
- Healthy Volunteers
- Interventions
- Reformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2007-06
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionReformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)PhasePhase 1Registry statusCompletedOpioid and Cannabinoid Pharmacokinetic Interactions
NCT00308555 · start 2006-05
Registered record
- Registry ID
- NCT00308555
- Conditions
- Pain
- Interventions
- Cannabis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2009-03
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionCannabisPhasePhase 1Registry statusCompleted